83 related articles for article (PubMed ID: 32943993)
21. Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation.
Fujii S; Ito K; Ito Y; Ochiai A
J Biol Chem; 2008 Jun; 283(25):17324-32. PubMed ID: 18430739
[TBL] [Abstract][Full Text] [Related]
22. [Expressions of EZH2 and RUNX3 in renal cell carcinoma and their clinical significance].
Wang G; Qin W; Zheng J; Wei M; Zhou X; Wang H; Wen W
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Jan; 29(1):82-4, 88. PubMed ID: 23294722
[TBL] [Abstract][Full Text] [Related]
23. Decreased expression of RUNX3 is correlated with tumor progression and poor prognosis in patients with esophageal squamous cell carcinoma.
Sugiura H; Ishiguro H; Kuwabara Y; Kimura M; Mitsui A; Mori Y; Ogawa R; Katada T; Harata K; Fujii Y
Oncol Rep; 2008 Mar; 19(3):713-9. PubMed ID: 18288406
[TBL] [Abstract][Full Text] [Related]
24. Oncogenic RUNX3: A Link between p53 Deficiency and MYC Dysregulation.
Date Y; Ito K
Mol Cells; 2020 Feb; 43(2):176-181. PubMed ID: 31991537
[TBL] [Abstract][Full Text] [Related]
25. RUNX3 Promotes the Tumorigenic Phenotype in KGN, a Human Granulosa Cell Tumor-Derived Cell Line.
Chen H; Crosley P; Azad AK; Gupta N; Gokul N; Xu Z; Weinfeld M; Postovit LM; Pangas SA; Hitt MM; Fu Y
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31311113
[TBL] [Abstract][Full Text] [Related]
26. Curcumin decreases Warburg effect in cancer cells by down-regulating pyruvate kinase M2 via mTOR-HIF1α inhibition.
Siddiqui FA; Prakasam G; Chattopadhyay S; Rehman AU; Padder RA; Ansari MA; Irshad R; Mangalhara K; Bamezai RNK; Husain M; Ali SM; Iqbal MA
Sci Rep; 2018 May; 8(1):8323. PubMed ID: 29844464
[TBL] [Abstract][Full Text] [Related]
27. Decreased expression of MGMT in correlation with aberrant DNA methylation in esophageal cancer patients from North India.
Rehman AU; Saikia S; Iqbal MA; Ahmad I; Sadaf ; Anees A; Aravinda PS; Mishra PK; Hedau S; Saluja SS; Medhi S; Husain SA
Tumour Biol; 2017 Jun; 39(6):1010428317705770. PubMed ID: 28621225
[TBL] [Abstract][Full Text] [Related]
28. Alteration in the expression of MGMT and RUNX3 due to non-CpG promoter methylation and their correlation with different risk factors in esophageal cancer patients.
Saikia S; Rehman AU; Barooah P; Sarmah P; Bhattacharyya M; Deka M; Deka M; Goswami B; Husain SA; Medhi S
Tumour Biol; 2017 May; 39(5):1010428317701630. PubMed ID: 28468586
[TBL] [Abstract][Full Text] [Related]
29. Threonine 209 phosphorylation on RUNX3 by Pak1 is a molecular switch for its dualistic functions.
Kumar A; Singhal M; Chopra C; Srinivasan S; Surabhi RP; Kanumuri R; Tentu S; Jagadeeshan S; Sundaram S; Ramanathan K; Shankar Pitani R; Muthuswamy B; Abhijit S; Nair AS; Venkatraman G; Rayala SK
Oncogene; 2016 Sep; 35(37):4857-65. PubMed ID: 26898755
[TBL] [Abstract][Full Text] [Related]
30. Aberrant overexpression of EZH2 and H3K27me3 serves as poor prognostic biomarker for esophageal squamous cell carcinoma patients.
Liu F; Gu L; Cao Y; Fan X; Zhang F; Sang M
Biomarkers; 2016; 21(1):80-90. PubMed ID: 26631178
[TBL] [Abstract][Full Text] [Related]
31. FLT3-ITD drives Ara-C resistance in leukemic cells via the induction of RUNX3.
Damdinsuren A; Matsushita H; Ito M; Tanaka M; Jin G; Tsukamoto H; Asai S; Ando K; Miyachi H
Leuk Res; 2015 Dec; 39(12):1405-13. PubMed ID: 26475207
[TBL] [Abstract][Full Text] [Related]
32. RUNX3 contributes to carboplatin resistance in epithelial ovarian cancer cells.
Barghout SH; Zepeda N; Vincent K; Azad AK; Xu Z; Yang C; Steed H; Postovit LM; Fu Y
Gynecol Oncol; 2015 Sep; 138(3):647-55. PubMed ID: 26186909
[TBL] [Abstract][Full Text] [Related]
33. RUNX3 Controls a Metastatic Switch in Pancreatic Ductal Adenocarcinoma.
Whittle MC; Izeradjene K; Rani PG; Feng L; Carlson MA; DelGiorno KE; Wood LD; Goggins M; Hruban RH; Chang AE; Calses P; Thorsen SM; Hingorani SR
Cell; 2015 Jun; 161(6):1345-60. PubMed ID: 26004068
[TBL] [Abstract][Full Text] [Related]
34. Diverse involvement of EZH2 in cancer epigenetics.
Völkel P; Dupret B; Le Bourhis X; Angrand PO
Am J Transl Res; 2015; 7(2):175-93. PubMed ID: 25901190
[TBL] [Abstract][Full Text] [Related]
35. Effect and mechanism of RUNX3 gene on biological characteristics of human esophageal squamous cell carcinoma (ESCC).
Chen H; Wang Z; Wang S; Zhang Z; Shi S
Med Oncol; 2015 Jan; 32(1):357. PubMed ID: 25428380
[TBL] [Abstract][Full Text] [Related]
36. A study on genetic variants of Fibroblast growth factor receptor 2 (FGFR2) and the risk of breast cancer from North India.
Siddiqui S; Chattopadhyay S; Akhtar MS; Najm MZ; Deo SV; Shukla NK; Husain SA
PLoS One; 2014; 9(10):e110426. PubMed ID: 25333473
[TBL] [Abstract][Full Text] [Related]
37. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.
Ferlay J; Soerjomataram I; Dikshit R; Eser S; Mathers C; Rebelo M; Parkin DM; Forman D; Bray F
Int J Cancer; 2015 Mar; 136(5):E359-86. PubMed ID: 25220842
[TBL] [Abstract][Full Text] [Related]
38. Regulation and Role of EZH2 in Cancer.
Yamaguchi H; Hung MC
Cancer Res Treat; 2014 Jul; 46(3):209-22. PubMed ID: 25038756
[TBL] [Abstract][Full Text] [Related]
39. RUNX3 facilitates growth of Ewing sarcoma cells.
Bledsoe KL; McGee-Lawrence ME; Camilleri ET; Wang X; Riester SM; van Wijnen AJ; Oliveira AM; Westendorf JJ
J Cell Physiol; 2014 Dec; 229(12):2049-56. PubMed ID: 24812032
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathological and prognostic significance of chemokine receptor CXCR4 overexpression in patients with esophageal cancer: a meta-analysis.
Wu J; Wu X; Liang W; Chen C; Zheng L; An H
Tumour Biol; 2014 Apr; 35(4):3709-15. PubMed ID: 24326770
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
